Keshtvarz, M.; Mahboobi, M.; Kieliszek, M.; Miecznikowski, A.; Sedighian, H.; Rezaei, M.; Haghighi, M.A.; Zareh, Z.; Rezaei, E.
Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. Toxins 2021, 13, 785.
https://doi.org/10.3390/toxins13110785
AMA Style
Keshtvarz M, Mahboobi M, Kieliszek M, Miecznikowski A, Sedighian H, Rezaei M, Haghighi MA, Zareh Z, Rezaei E.
Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. Toxins. 2021; 13(11):785.
https://doi.org/10.3390/toxins13110785
Chicago/Turabian Style
Keshtvarz, Maryam, Mahdieh Mahboobi, Marek Kieliszek, Antoni Miecznikowski, Hamid Sedighian, Milad Rezaei, Mohammad Ali Haghighi, Zahra Zareh, and Ehsan Rezaei.
2021. "Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study" Toxins 13, no. 11: 785.
https://doi.org/10.3390/toxins13110785
APA Style
Keshtvarz, M., Mahboobi, M., Kieliszek, M., Miecznikowski, A., Sedighian, H., Rezaei, M., Haghighi, M. A., Zareh, Z., & Rezaei, E.
(2021). Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. Toxins, 13(11), 785.
https://doi.org/10.3390/toxins13110785
